Acorda Therapeutics Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Acorda Therapeutics Inc.

An SI Board Since October 2003

Posts	SubjectMarks	Bans	Symbol
120	6	0	ACOR

Emcee: michael_f_murphy	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
70	Sidney Wolfe is on the panel. That ought to be interesting.	rkrw	1	10/9/2009
69	Tuck, Not getting too personal in this exchange, I've mentioned that I don&#	Arthur Radley	-	10/9/2009
68	Maybe this explains the unusual language you pointed to on the valuation thread.	tuck	1	10/9/2009
67	Yes, exactly my thoughts. I hope that if there's a majority of MS specialist	idos	1	10/9/2009
66	IDOS, That is what I don't understand.......the FDA and ACOR clearly agreed	Arthur Radley	-	10/9/2009
65	ACOR's primary endpoint in the two SPA-supported trials was a responder-base	idos	-	10/9/2009
64	Jim, Appears that we have the placebo issue all over again. As you know........I	Arthur Radley	-	10/9/2009
63	I have only gotten through 40 pages of the 177. It does have a negative tone.	IRWIN JAMES FRANKEL	-	10/9/2009
62	The meeting is going to be very interesting. Have to trade!	kenhott	-	10/9/2009
61	Stock is under heavy pressure in Pre-Market......several hundred thousand shares	Arthur Radley	-	10/9/2009
60	Briefing doc (PDF 177 pgs): fda.gov Questions: fda.gov	IRWIN JAMES FRANKEL	-	10/9/2009
59	Regarding current stock price has priced in the approval, I think the complexity	kenhott	-	10/8/2009
58	Ken, First let me thank you for taking the time to share that information about	Arthur Radley	-	10/7/2009
57	Don't have that much time so I will just make a couple of comments. I am po	kenhott	-	10/7/2009
56	Thanks Fred. I have copied the text of your link below. I am traveling but if	kenhott	-	10/6/2009
55	ft.com	fred hayes	-	10/5/2009
54	I respect Sendek as a biotech analyst... cnbc.com	Arthur Radley	-	9/28/2009
53	OT-What?? The dog or your little brother never ate your homework???	kenhott	-	9/16/2009
52	finance.yahoo.com How can anyone make a mistake in reporting data??????????????	Arthur Radley	-	9/15/2009
51	Couple of more abstracts from the ECTRIMS. Thursday, September 10, 2009, 15:15	kenhott	1	9/11/2009
50	Couple of more abstracts at the ECTRIMS. Thursday, September 10, 2009, 15:15 -	kenhott	1	9/11/2009
49	Deleted.	idos	-	9/10/2009
48	Acorda Therapeutics Announces Interim Analysis of Two-Year Efficacy and Safety D	kenhott	-	9/10/2009
47	Hope you are right. ACOR mgt gives me some willies because I think they don'	kenhott	-	9/3/2009
46	Only thing is that the panel is due on October 14 and the PDUFA date is only a w	idos	-	9/3/2009

Go to reply# or date (mm/dd/yy):